注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Allogene Therapeutics Inc是一家临床阶段的免疫肿瘤公司。该公司专注于用于治疗癌症的基因工程同种异体T细胞疗法的开发和推广业务。该公司致力于利用蛋白质工程、基因编辑、基因插入和先进的T细胞制造技术开发多种同种异体嵌合抗原受体(CAR)T细胞候选产品。其先进的候选产品ALLO-501和ALLO-501A是工程化的靶向CD19的同种异体CAR T细胞疗法。CD19是一种在B细胞细胞表面表达的蛋白质,是B细胞驱动的血液恶性肿瘤的有效靶点。它还正在开发用于多发性骨髓瘤、透明细胞肾细胞癌(ccRCC)和其他血癌和实体瘤的工程化同种异体CAR T细胞候选产品。其主要候选产品包括ALLO-501、ALLO-501A、ALLO-715、ALLO-715、ALLO-605、ALLO-316和ALLO-647。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Joshua A. Kazam | 44 | 2017 | Co-Founder & Director |
Arie S. Belldegrun | 72 | 2017 | Co-Founder & Executive Chairman |
David D. Chang | 61 | 2018 | Co-Founder, President, CEO & Director |
John A. DeYoung | 58 | 2018 | Independent Director |
Matthew Porteus | 56 | - | Member of Scientific Advisory Board |
Antonius N.M. Schumacher | - | - | Chairman of Scientific Advisory Board |
Donald B. Kohn | - | - | Member of Scientific Advisory Board |
Malcolm K. Brenner | 69 | 2019 | Member of Scientific Advisory Board |
Todd B. Sisitsky | 51 | 2018 | Independent Director |
Franz Bernhard Humer | 76 | 2018 | Independent Director |
David Bonderman | 80 | 2018 | Lead Independent Director |
Deborah M. Messemer | 64 | 2018 | Independent Director |
Stephen J. Forman | 73 | 2019 | Member of Scientific Advisory Board |
Stephan A. Grupp | - | 2020 | Member of Scientific Advisory Board |
Jae Park | - | 2021 | Member of Scientific Advisory Board |
Thomas F. Gajewski | - | 2020 | Member of Scientific Advisory Board |
Stephen L. Mayo | 61 | 2022 | Independent Director |
Vicki L. Sato | 74 | 2021 | Independent Director |
Elizabeth A. Barrett | 61 | 2021 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核